Aprea Therapeutics, Inc. (APRE) Financial Statements
Industry: Pharmaceutical Preparations
In fiscal 2025, Aprea Therapeutics reported revenue of $0. Net income was -$12.6M, or -$1.93 per diluted share. Operating activities generated -$12.9M of cash, leaving -$12.9M of free cash flow. At fiscal year end, Aprea Therapeutics held $15.9M in total assets against $3.5M in total liabilities, including $14.6M of cash and equivalents.
Open the full interactive Aprea Therapeutics financials → Quarterly statements, key ratios, valuation history and price charts.
Aprea Therapeutics Key Stats
| Share Price | $0.60 |
|---|---|
| Market Cap | $32.1M |
| 52-Week Range | $0.56 – $1.65 |
| Shares Outstanding | 53.5 million (basic, 2026 Q2) |
Aprea Therapeutics Income Statement
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 | $0 |
| Operating Income | — | — | — | -$15.5M | -$14.3M | -$13.2M |
| Pre-Tax Income | -$53.5M | -$37.1M | -$112.7M | -$14.3M | -$13.0M | -$12.6M |
| Income Tax | $0 | $0 | $0 | $0 | $0 | $0 |
| Net Income | -$53.5M | -$37.1M | -$112.7M | -$14.3M | -$13.0M | -$12.6M |
| Diluted EPS | -$50.60 | -$34.80 | -$68.16 | -$3.95 | -$2.45 | -$1.93 |
Aprea Therapeutics Quarterly Results
| 2025 Q3 | 2025 Q4 | 2026 Q1 | 2026 Q2 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| Net Income | -$3.0M | -$2.5M | -$3.3M | -$3.6M |
| Diluted EPS | -$0.47 | -$0.38 | -$0.22 | -$0.07 |
Aprea Therapeutics Balance Sheet
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Cash & Equivalents | $89.0M | $53.1M | $28.8M | $21.6M | $22.8M | $14.6M |
| Current Assets | $92.4M | $56.6M | $30.2M | $22.5M | $23.6M | $15.6M |
| Total Assets | $92.8M | $56.8M | $30.2M | $22.7M | $24.0M | $15.9M |
| Current Liabilities | $15.3M | $7.3M | $3.2M | $4.4M | $3.4M | $2.8M |
| Total Liabilities | $15.4M | $7.3M | $3.2M | $5.7M | $4.7M | $3.5M |
| Shareholders' Equity | $77.4M | $49.5M | $25.6M | $17.0M | $19.3M | $12.4M |
Aprea Therapeutics Cash Flow Statement
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Cash From Operations | -$41.8M | -$37.7M | -$25.0M | -$12.2M | -$13.6M | -$12.9M |
| Cash From Investing | -$25,709 | — | — | -$93,093 | -$15,478 | — |
| Cash From Financing | $150,949 | $1.7M | $682,973 | $5.1M | $14.8M | $4.6M |
| Free Cash Flow | -$41.8M | -$37.7M | -$25.0M | -$12.3M | -$13.6M | -$12.9M |
Figures from Aprea Therapeutics' 10-K and 10-Q filings with the SEC, as of 2026-10-14. Fiscal years follow the company's own reporting calendar. EPS and share counts are adjusted for later stock splits. See the full Aprea Therapeutics financials page for every line item.
Aprea Therapeutics Company Profile
| Ticker | APRE |
|---|---|
| Exchange | Nasdaq |
| Industry | Pharmaceutical Preparations |
| Headquarters | Doylestown, Pennsylvania |
| Incorporated in | Delaware |
| Fiscal Year End | December 31 |
| SEC Filer Category | Non-accelerated filer, smaller reporting company |
| SEC CIK | 0001781983 |
Frequently Asked Questions
What was Aprea Therapeutics' revenue in fiscal 2025?
Aprea Therapeutics (APRE) reported revenue of $0 for fiscal 2025.
What is Aprea Therapeutics' annual revenue history?
Aprea Therapeutics' annual revenue by fiscal year: 2020: $0; 2021: $0; 2022: $0; 2023: $0; 2024: $0; 2025: $0.
What was Aprea Therapeutics' net income in fiscal 2025?
Aprea Therapeutics reported net income of -$12.6M for fiscal 2025.
What was Aprea Therapeutics' earnings per share (EPS) in fiscal 2025?
Aprea Therapeutics' diluted EPS was -$1.93 for fiscal 2025 (adjusted for any later stock splits).
How much free cash flow did Aprea Therapeutics generate in fiscal 2025?
Aprea Therapeutics generated -$12.9M of free cash flow in fiscal 2025.
What was Aprea Therapeutics' revenue last quarter?
In its most recent reported quarter (2026 Q2), Aprea Therapeutics reported revenue of $0.
How many shares of Aprea Therapeutics are outstanding?
Aprea Therapeutics reported a weighted average of 53.5 million basic shares outstanding in 2026 Q2.
What is Aprea Therapeutics' market cap?
Based on its latest closing price, Aprea Therapeutics (APRE) has a market capitalization of about $32.1M.
When does Aprea Therapeutics' fiscal year end?
Aprea Therapeutics' fiscal year end, as registered with the SEC, is December 31.
Where is Aprea Therapeutics headquartered?
Aprea Therapeutics lists its business address in Doylestown, Pennsylvania in its SEC filings.